Floatz logo

Jab-21822

Appendiceal Cancer

Allist Pharmaceuticals, Inc.Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

21 Active assets in the Appendiceal Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 2BB
MITOMYCIN C
National Cancer Institute (NCI)
Phase 2B
Sodium Thiosulfate
National Cancer Institute (NCI)
Phase 2B
Nilotinib
National Cancer Institute (NCI)
Phase 2B
Evomela
University of Kansas Medical Center
Phase 2CCC

View all 26 →

Same molecule, other indications

Jab-21822 is also rated in:

KRAS P.G12CDormant
B
Indicative ·
60 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
56 / 100
View asset →
neoplasmDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →